阑尾炎严重程度评分系统2.0的开发与验证
本研究在荷兰11家医院前瞻性纳入2020年1月至2021年8月因疑似急性阑尾炎手术的成人患者,外部验证SAS未达到预设的95%敏感性(83.6%)和阴性预测值(85.0%)目标,遂利用同一队列开发SAS 2.0,并在565例时间验证队列中外部验证(C统计量0.86)。
要点
- SAS外部验证敏感性83.6%(95% CI 78.8-87.6),阴性预测值85.0%(95% CI 80.6-88.8),未达预设95%目标。
- SAS 2.0内部验证C统计量0.87(95% CI 0.84-0.89),外部验证C统计量0.86(95% CI 0.82-0.89)。
- SAS 2.0可计算患者个体化复杂阑尾炎概率及95% CI,有助于非手术治疗决策讨论。
核心结论
- SAS外部验证未能准确区分复杂与非复杂阑尾炎,新开发并外部验证的SAS 2.0能以高准确度评估急性阑尾炎患者个体化复杂阑尾炎概率。
研究设计与样本
- 前瞻性研究,纳入2020年1月至2021年8月荷兰11家医院因疑似急性阑尾炎手术的成人患者,共1360例,其中463例(34.5%)为复杂阑尾炎;SAS在795例中预测,SAS 2.0在565例时间验证队列中外部验证。
主要发现
- SAS验证敏感性83.6%(95% CI 78.8-87.6),阴性预测值85.0%(95% CI 80.6-88.8),未达到预设95%目标。
- SAS 2.0内部验证C统计量0.87(95% CI 0.84-0.89),外部验证C统计量0.86(95% CI 0.82-0.89)。
- SAS 2.0设计用于计算患者个体化复杂阑尾炎概率及95% CI。
关键数值与推荐
- SAS 2.0基于多变量回归开发,纳入临床、生化和影像学发现。
- SAS 2.0内部验证C统计量0.87(95% CI 0.84-0.89),外部验证C统计量0.86(95% CI 0.82-0.89)。
临床怎么用
- 作者认为,使用该患者特异性风险评估工具可在考虑和讨论急性阑尾炎非手术治疗时提供帮助。
局限性
- SAS外部验证敏感性和阴性预测值未达到预设的95%目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: When considering nonoperative treatment in a patient with acute appendicitis, it is crucial to accurately rule out complicated appendicitis. The Atema score, also referred to as the Scoring System of Appendicitis Severity (SAS), has been designed to differentiate between uncomplicated and complicated appendicitis but has not been prospectively externally validated. OBJECTIVE: To externally validate the SAS and, in case of failure, to develop an improved SAS (2.0) for estimating the probability of complicated appendicitis. DESIGN, SETTING, AND PARTICIPANTS: This prospective study included adult patients who underwent operations for suspected acute appendicitis at 11 hospitals in the Netherlands between January 2020 and August 2021. MAIN OUTCOMES AND MEASURES: Appendicitis severity was predicted according to the SAS in 795 patients and its sensitivity and negative predictive value (NPV) for complicated appendicitis were calculated. Since the predefined targets of 95% for both were not met, the SAS 2.0 was developed using the same cohort. This clinical prediction model was developed with multivariable regression using clinical, biochemical, and imaging findings. The SAS 2.0 was externally validated in a temporal validation cohort consisting of 565 patients. RESULTS: In total, 1360 patients were included, 463 of whom (34.5%) had complicated appendicitis. Validation of the SAS resulted in a sensitivity of 83.6% (95% CI, 78.8-87.6) and an NPV of 85.0% (95% CI, 80.6-88.8), meaning that the predefined targets were not achieved. Therefore, the SAS 2.0 was developed, internally validated (C statistic, 0.87; 95% CI, 0.84-0.89), and subsequently externally validated (C statistic, 0.86; 95% CI, 0.82-0.89). The SAS 2.0 was designed to calculate a patient's individual probability of having complicated appendicitis along with a 95% CI. CONCLUSIONS AND RELEVANCE: In this study, external validation of the SAS fell short in accurately distinguishing complicated from uncomplicated appendicitis. The newly developed and externally validated SAS 2.0 was able to assess an individual patient's probability of having complicated appendicitis with high accuracy in patients with acute appendicitis. Use of this patient-specific risk assessment tool can be helpful when considering and discussing nonoperative treatment of acute appendicitis with patients.
引用
- Scheijmans JCG, Bom WJ, Ghori UH, et al. Development and Validation of the Scoring System of Appendicitis Severity 2.0. JAMA Surg. 2024. PMID: 38536188. doi:10.1001/jamasurg.2024.0235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。